Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan

Middle East, North Africa, Afghanistan & Pakistan: Access to anti-retroviral drugs, female was 39.7% in 2024. ◆ Volatile

Latest (2024)
39.7%
Change on year
up 5.2%
Rank
17th
of 19 groups
All-time high
39.7%
in 2024
All-time low
1.9%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan, 2000–2024

0102030402000201220242000: 1.9 %2001: 2.3 %2002: 2.6 %2003: 5.4 %2004: 4.7 %2005: 5.8 %2006: 6.8 %2007: 7.9 %2008: 9 %2009: 10.9 %2010: 12.8 %2011: 14 %2012: 16.4 %2013: 18.3 %2014: 21 %2015: 22.8 %2016: 25.3 %2017: 27.5 %2018: 30 %2019: 31.4 %2020: 31.5 %2021: 34.2 %2022: 35.1 %2023: 37.8 %2024: 39.7 %

Source: UNAIDS estimates. Measured in %.

Analysis

Middle East, North Africa, Afghanistan & Pakistan recorded 39.7% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

That represents a change of up 5.2% on the previous year and up 89.3% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan peaked at 39.7% in 2024 and was at its lowest, 1.9%, in 2000.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Middle East, North Africa, Afghanistan & Pakistan, 2000 to 2024.
Year % Change
2000 1.9%
2001 2.3% +17.7%
2002 2.6% +13.3%
2003 5.4% +108.7%
2004 4.7% -12.3%
2005 5.8% +22.0%
2006 6.8% +17.1%
2007 7.9% +16.3%
2008 9.0% +14.8%
2009 10.9% +20.2%
2010 12.8% +17.8%
2011 14.0% +9.7%
2012 16.4% +17.1%
2013 18.3% +11.6%
2014 21.0% +14.4%
2015 22.8% +8.5%
2016 25.3% +11.3%
2017 27.5% +8.6%
2018 30.0% +9.1%
2019 31.4% +4.5%
2020 31.5% +0.5%
2021 34.2% +8.6%
2022 35.1% +2.6%
2023 37.8% +7.4%
2024 39.7% +5.2%

Biggest year-on-year movements

Years where Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2003 +108.7% 2.6% 5.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 5.7% 1.9% 10.9% 10
2010s 22.0% 12.8% 31.4% 10
2020s 35.7% 31.5% 39.7% 5

Countries ranked near Middle East, North Africa, Afghanistan & Pakistan

  1. 14 Liberia 96.0% compare
  2. 14 Sweden 96.0% compare
  3. 14 Togo 96.0% compare
  4. 14 United Kingdom 96.0% compare
  5. 14 Zambia 96.0% compare
  6. 19 Cameroon 95.0% compare
  7. 19 Sierra Leone 95.0% compare
  8. 19 Tajikistan 95.0% compare

See the full ranking of 160 places →

More gender data for Middle East, North Africa, Afghanistan & Pakistan

All data for Middle East, North Africa, Afghanistan & Pakistan →

Frequently asked questions

What is access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan?
Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan was 39.7% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Middle East, North Africa, Afghanistan & Pakistan?
The highest recorded value was 39.7% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Middle East, North Africa, Afghanistan & Pakistan?
The lowest recorded value was 1.9% in 2000.
How does Middle East, North Africa, Afghanistan & Pakistan rank for access to anti-retroviral drugs, female?
Middle East, North Africa, Afghanistan & Pakistan ranks 17th out of 19 groups with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Middle East, North Africa, Afghanistan & Pakistan?
Over the last ten years it is up 89.3%. The long-run trend across the full record is volatile.
Where does this Middle East, North Africa, Afghanistan & Pakistan data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan. Statizoid, drawing on UNAIDS estimates. Retrieved 18 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/middle-east-north-africa-afghanistan-and-pakistan/">Access to anti-retroviral drugs, female in Middle East, North Africa, Afghanistan & Pakistan</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.